Almeida Lima, K.; Osawa, I.Y.A.; Ramalho, M.C.C.; de Souza, I.; Guedes, C.B.; Souza Filho, C.H.D.d.; Monteiro, L.K.S.; Latancia, M.T.; Rocha, C.R.R.
Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil. Biomedicines 2023, 11, 1081.
https://doi.org/10.3390/biomedicines11041081
AMA Style
Almeida Lima K, Osawa IYA, Ramalho MCC, de Souza I, Guedes CB, Souza Filho CHDd, Monteiro LKS, Latancia MT, Rocha CRR.
Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil. Biomedicines. 2023; 11(4):1081.
https://doi.org/10.3390/biomedicines11041081
Chicago/Turabian Style
Almeida Lima, Karoline, Isabeli Yumi Araújo Osawa, Maria Carolina Clares Ramalho, Izadora de Souza, Camila Banca Guedes, Cláudio Henrique Dahne de Souza Filho, Linda Karolynne Seregni Monteiro, Marcela Teatin Latancia, and Clarissa Ribeiro Reily Rocha.
2023. "Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil" Biomedicines 11, no. 4: 1081.
https://doi.org/10.3390/biomedicines11041081
APA Style
Almeida Lima, K., Osawa, I. Y. A., Ramalho, M. C. C., de Souza, I., Guedes, C. B., Souza Filho, C. H. D. d., Monteiro, L. K. S., Latancia, M. T., & Rocha, C. R. R.
(2023). Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil. Biomedicines, 11(4), 1081.
https://doi.org/10.3390/biomedicines11041081
